Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Multicenter Phase II Study of Maintenance Belantamab Mafodotin (Blenrep®) After BCMA-Directed Chimeric Antigen Receptor T-cell Therapy in Patients With Relapsed and/or Refractory Multiple Myeloma

NCT05117008 is registered in ClinicalTrials.gov with Medical College of Wisconsin as lead sponsor.

NCT NCT05117008
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05117008 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Multicenter Phase II Study of Maintenance Belantamab Mafodotin (Blenrep®) After BCMA-Directed Chimeric Antigen Receptor T-cell Therapy in Patients With Relapsed and/or Refractory Multiple Myeloma
Lead sponsor
Medical College of Wisconsin
Phase
Phase 2
Overall status
Terminated
Start date
July 19, 2022
Completion date
January 15, 2024
Enrollment
1 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

refractory multiple myeloma, relapse multiple myeloma